- Home
- SBFM
as 10-17-2024 4:00pm EST
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | FORT LAUDERDALE |
| Market Cap: | 3.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 153.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -142.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.42 - $660.00 | Next Earning Date: | 11-11-2024 |
| Revenue: | $30,481,982 | Revenue Growth: | 109.82% |
| Revenue Growth (this year): | 86.7% | Revenue Growth (next year): | 126.76% |
Latest Sunshine Biopharma Inc. News
SBFM Breaking Stock News: Dive into SBFM Ticker-Specific Updates for Smart Investing
ACCESSWIRE
22 days ago
Sunshine Biopharma Launches Two New Generic Prescription Drugs
ACCESSWIRE
a month ago
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
Insider Monkey
2 months ago
Is Sunshine Biopharma, Inc. (SBFM) The Best Rated Penny Stock To Buy According to Analysts?
ACCESSWIRE
2 months ago
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
ACCESSWIRE
2 months ago
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
ACCESSWIRE
2 months ago
Sunshine Biopharma Announces Reverse Stock Split
ACCESSWIRE
5 months ago
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
ACCESSWIRE
6 months ago
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
Compare SBFM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SBFM Sunshine Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.